AKT1 and hepatocellular carcinoma: Integrating current evidence, we analyze how sEVs drive HCC progression by: (a) modulating pivotal pathways (PI3K/AKT, Wnt/β-catenin); (b) reprogramming TME cellular composition/functionality; (c) enhancing malignant behaviors (proliferation, metastasis).